In July 2023, ZyVersa Therapeutics, Inc. announced the publication of a research article in the peer-reviewed journal Hepatology, highlighting the involvement of NLRP3 inflammasome-mediated IL-18 in liver fibrosis progression. The study, titled "Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis," examined serum IL-18 levels in patients with liver fibrosis or cirrhosis. In addition, the researchers conducted experiments using three distinct mouse models of liver fibrosis to further explore the role of IL-18 signaling in activating hepatic stellate cells
